

The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
According to the latest report by IMARC Group, titled “ Cancer/Tumor Profiling Market: Global Industry Trends, Share, Size, Growth, Opportunity and Foreca st 2022-2027
” the global cancer/tumor profiling market reached a strong growth in 2021.
Cancer/tumor profiling, also called biomarker testing, represents a laboratory test or procedure that is used for identifying specific proteins, gene mutations, and other biomarkers in a tumor tissue sample. It assists in therapeutic decision-making, routine diagnostics, and developing customized treatment therapies and plans for patients based on the severity of their diseases and genomic build-up. Consequently, cancer/tumor profiling finds wide-ranging applications in research, prognostics, the discovery of biomarkers, the development of screening and diagnostic techniques, etc.
Request Free Sample Report: https://www.imarcgroup.com/cancer-tumor-profiling-market/requestsample
The growing number of clinical trials and the increasing adoption of immunoassay techniques are among the primary factors driving the cancer/tumor profiling market. Moreover, the launch of various favorable policies by government bodies across countries for introducing numerous innovative techniques to reduce the time taken for the detection and identification of tumors is further catalyzing the market growth.
In line with this, several technological advancements in molecular biology techniques, such as nextgeneration sequencing (NGS), are augmenting the utilization of cancer/tumor profiling, which, in turn, is acting as another significant growth-inducing factor. Additionally, the elevating consumer inclination towards personalized medicines is also positively influencing the global market. Besides this, the inflating investments by pharmaceutical and biotechnology companies in R&D activities for developing new drug designing techniques and novel therapies are anticipated to fuel the cancer/tumor profiling market over the forecasted period. Looking forward, the market value is projected to reach a strong growth during the forecast period (2022-2027).
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.